DEVELOPMENT OF THE DESIGN OF THE PRECLINICAL TRIALS OF RADIOPHARMACEUTICALS FOR THE RADIONUCLIDE DIOAGNOSTICS AND THERAPY BASED ON THE AMBA PEPTIDE

Abstract


The present study is related to one of the promising areas of nuclear medicine: the use of peptides – bombesin analogues, labeled with 68Ga – for diagnosis and 177Lu – for therapy of prostate cancer. In the Russian Federation, preclinical trials of similar radiopharmaceutical drugs are in the study design stage. The aim of the current study was to develop the design of the preclinical study for the radiopharmaceutical drugs to assess the biodistribution of a peptide, an analogue of bombesin, intended for the diagnosis and treatment of prostate cancer.
The study was based on the meta-analysis of the available publications in peer-reviewed journals. The analysis was performed using the full-text archive of biomedical and life sciences journals PubMed Central for the following keywords: “radionuclide therapy”, “nuclear medicine”, “AMBA”, “68Ga” и “177Lu”. The study included the comparative analysis of the animal and patient samples, methods of data collection and results of the accumulation of radiopharmaceuticals in nodules and radiosensitive organs and tissues.
The results of the study allowed proposing the minimal requirements for the animal samples (at least 30 animals for each radiopharmaceutical), data collection (direct radiometry and PET) and time points (not less than 5 measurements in 120-240 minutes for the radiopharmaceuticals labeled with 68Ga and 5 measurements in 336 hours for the radiopharmaceuticals labeled with 177Lu) for the assessment of the biodistribution of the radiopharmaceuticals.


About the authors

Andrey A. Stanzhevsky

A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Saint Petersburg, Russia

Email: stanzhevsky@gmail.com

Russian Federation, 197758, Russia, Saint Petersburg, Pesochny settlement, Leningradskaya str., 70

Doctor of Medicine (MD), Deputy Director for research

Artem A. Mosunov

Peter the Great St.Petersburg Polytechnic University, Saint Petersburg, Russia

Email: zawq2000@gmail.com

Russian Federation, 195251, Russia, Saint Petersburg, Politechnicheskaya str., 29,

student

Larisa Chipiga

A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Saint Petersburg, Russia; Saint Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Saint Petersburg, Russia; Almazov National Medical Research Centre, Saint Petersburg, Russia

Author for correspondence.
Email: Larisa.chipiga@gmail.com

Russian Federation, 197758, Russia, Saint Petersburg, Pesochny settlement, Leningradskaya str., 70; 8 Mira street, Saint Petersburg, 197101, Russia; 197341, Russia, Saint Petersburg, akkuratova str., 2

Ph.D. in Engineering Sciences, Researcher at the laboratory of radiation hygiene of medical organizations, Researcher, docent

Aleksandr V. Vodovatov

Saint Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Saint Petersburg, Russia; Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia

Email: vodovatoff@gmail.com

Russian Federation, 8 Mira street, Saint Petersburg, 197101, Russia; 194100, Russia, Saint Petersburg, Litovskaya str., 2

Ph.D. in Biological Sciences, Head of radiation hygiene of medical organizations, Associate Professor, Department of Hygiene

Laura Naurzbaeva

Peter the Great Saint Petersburg Polytechnic University, Saint Petersburg, Russia

Email: naurzbaeva.laura@gmail.com

Russian Federation, 195251, Russia, Saint Petersburg, Politechnicheskaya str., 29,

student

Stanislav M. Kushnarenko

Peter the Great Saint Petersburg Polytechnic University, Saint Petersburg, Russia

Email: arichikaaris@mail.ru

Russian Federation, 195251, Russia, Saint Petersburg, Politechnicheskaya str., 29,

student

Dmitry D. Lavreshov

Peter the Great Saint Petersburg Polytechnic University, Saint Petersburg, Russia

Email: ldd99@mail.ru

Russian Federation, 195251, Russia, Saint Petersburg, Politechnicheskaya str., 29,

student

Anna E. Petrova

Peter the Great Saint Petersburg Polytechnic University, Saint Petersburg, Russia

Email: anyapetrova2797@gmail.com

Russian Federation, 195251, Russia, Saint Petersburg, Politechnicheskaya str., 29,

student

References

  1. Bass RT, Buckwalter BL, Patel BP, et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol.1996; 50: 709–15.
  2. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy Nucl Med.2017;58(suppl):61S–66S. doi: 10.2967/jnumed.116.186783.
  3. Пойда, М.Д. 68Ga-ПСМА – меченный биомаркер для позитронной эмиссионной томографии (обзор литературы) / М.Д. Пойда, Д.В. Рыжкова, А.А. Станжевский. – doi: 10.18705/2311-4495-2018-5-5-46-52 // Трансляционная медицина. 2018. – Т. 5. – №5. – С. 46–52.
  4. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3 (1): 81–5.
  5. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006; 26 (14): 5310–24. doi: 10.1128/MCB.00084-06.
  6. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91 (3): 528–39. doi: 10.1002/jcb.10661.
  7. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003; 9 (17): 6357–62.
  8. Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015; 5 (12): 1388–401. doi: 10.7150/thno.13348.
  9. de Visser M, Bernard HF, Erion JL, et al. Novel 111In-labelled bombesin analogues formolecular imaging of prostate tumours. Eur J Nucl Med MolImaging 2007; 34: 1228–38. doi: 10.1007/s00259-006-0356-3.
  10. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 18:1457–66. doi: 10.1093/annonc/mdm058.
  11. Xiao D, Wang J, Hampton LL, et al. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 2001; 264: 95–103. doi: 10.1016/s0378-1119(00)00596-5.
  12. Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets. 2006; 5 (2): 197–204. doi: 10.2174/187152706776359673.
  13. Lantry LE, Cappelletti E, Maddalena ME, et al. Lu-AMBA: synthesis and characterization of aselective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006; 47 (7): 1144–52.
  14. Schroeder RPJ, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010; 37 (7): 1386–96. doi: 10.1007/s00259-010-1388-2.
  15. Schroeder RPJ, van Weerden WM, Krenning EP, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 2011; 38 (7): 1257–66. doi: 10.1007/s00259-011-1775-3.
  16. Dam JH, Olsen BB, Baun C, et al. In vivo evaluation of a bombesin analogue labeled with Ga-68 and Co-55/57. Mol. Imaging Biol. 2016; 18 (3): 368−76. doi: 10.1007/s11307-015-0911-z.
  17. Pandey U, Mukherjee A, Jindal A, et al. Preparation and evaluation of a single vial AMBA kit for 68Ga labeling with potential for imaging of GRP receptor-positive cancers. J Radioanal Nucl Chem. 2016; 307: 1115–24. doi: 10.1007/s10967-015-4290-3.
  18. Prignon A, Nataf V, Provost C, et al. 68Ga-AMBA and 18F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. Nucl Med Biol. 2015; 42 (2): 92–8. doi: 10.1016/j.nucmedbio.2014.10.003.
  19. Layman R. Quantitative PET/CT Imaging Based Biodistribution Validated in a Porcine Model using a Targeted Peptide Radiotracer, AMBA. Ohio State University; 2013.
  20. Baum RP, Prasad V, Mutloka N, et al. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: first results [abstract]. J Nucl Med. 2007; 48 (Suppl 2): 79.
  21. Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA Biodistribution, Radiotherapeutic Efficacy, Imaging, and Autoradiography in Prostate Cancer Models with Low GRP-R Expression. Journal of Nuclear Medicine. 2009; 50 (12): 2017–24. doi: 10.2967/jnumed.109.064444.
  22. Liu I, Chang C-H, Ho C, et al. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010; 30: 4039–48.

Statistics

Views

Abstract - 14

PDF (Russian) - 4

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Pharmacy Formulas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies